

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS LLC and  
PAR PHARMACEUTICAL, INC.  
Petitioner

v.

JAZZ PHARMACEUTICALS, INC.  
Patent Owner

---

CASE IPR2015-00547  
Patent 7,765,107

---

**PAR PHARMACEUTICAL, INC.'S UPDATED MANDATORY NOTICES  
PURSUANT TO 37 C.F.R. § 42.8(A)(3)**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Petitioner Par Pharmaceutical, Inc. (“Par”) is a real-party-in-interest for this proceeding. Out of an abundance of caution, and as a result of ongoing integration and reorganization activities, Petitioner identifies the following additional entities as real-parties-in-interest who, going forward, may have control over this proceeding: Endo International PLC; Endo DAC; Endo Management Limited; Endo Luxembourg Holding Company S.a.r.l.; Endo Luxembourg Finance Company I S.a.r.l.; Endo U.S. Inc.; Endo US Holdings Luxembourg I S.a.r.l.; Endo US Holdings Luxembourg II S.a.r.l.; Endo Health Solutions Inc.; Hawk Acquisition Ireland Limited; and Par Pharmaceutical Companies, Inc.<sup>1</sup>

---

<sup>1</sup> Patent Owner Jazz Pharmaceuticals, Inc. has asserted that various entities, including Par Pharmaceutical Holdings, Inc., Sky Growth Intermediate Holdings Corporation I, Sky Growth Intermediate Holdings Corporation II and an entity named Par Pharmaceutical Companies, Inc., were improperly not named as real-parties-in-interest in their Preliminary Response (Paper No. 10). As a result of Endo International PLC’s acquisition of Par Pharmaceutical, Inc., Petitioner notes that Sky Growth Intermediate Holdings Corporation I, Sky Growth Intermediate Holdings Corporation II and Par Pharmaceutical Companies, Inc. were merged into and reorganized with Par Pharmaceutical Holdings, Inc., which was immediately thereafter re-named Par Pharmaceutical Companies, Inc. For clarity, the newly

Respectfully Submitted,

Date: October 21, 2015



---

Matthew C. Ruedy (Reg. No. 64,823)  
MADDOX EDWARDS, P.L.L.C.  
1900 K Street NW – Suite 725  
Washington, D.C. 20006  
(202) 830-0779  
mruedy@meiplaw.com

*Attorney for Petitioners*

---

reorganized Par Pharmaceutical Companies, Inc. is not identical to the entity previously known by the same name.

**CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e))**

The undersigned hereby certifies that the above-captioned “Par Pharmaceutical, Inc.’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8(A)(3)” was served in its entirety on October 21, 2015 by filing these documents through the Patent Review Processing System, as well as e-mailing copies to the following:

F. Dominic Cerrito  
Eric C. Stops  
Gabriel P. Brier  
QUINN EMANUEL URQUHART &  
SULLIVAN LLP  
51 Madison Avenue  
22nd Floor  
New York, NY 10010  
nickcerrito@quinnemanuel.com

John V. Biernacki  
JONES DAY  
North Point  
901 Lakeside Avenue  
Cleveland, OH 44114  
jvbiernacki@jonesday.com

Date: October 21, 2015



---

Matthew C. Ruedy (Reg. No. 64,823)  
MADDOX EDWARDS, P.L.L.C.  
1900 K Street NW – Suite 725  
Washington, D.C. 20006  
(202) 830-0779  
mruey@meiplaw.com

*Attorney for Petitioners*